Journal: MicrobiologyOpen

Article Title: The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics

doi: 10.1002/mbo3.222

Figure Lengend Snippet: Lantibiotic structural elements. (A) Covalent structures for mutacin 1140, epidermin, and nisin with the lanthionine rings labeled from N- to C-terminus. (B) Leader sequence alignments of structurally related class I type AI lantibiotics; that is, mutacin 1140 produced by Streptococcus mutans , nisin produced by Lactococcus lactis , subtilin produced by Bacillus subtilis , epidermin produced by Staphylococcus epidermidis , gallidermin produced by Staphylococcus gallinarium , Pep5 produced by Staphylococcus epidermidis, epilancin K7 produced by Staphylococcus epidermidis (Gross and Morell ; Allgaier et al. ; Kellner et al. ; Kaletta et al. ; Piard et al. ; Klein and Entian ; Vandekamp et al. ; Hillman et al. ). (C) Secondary structure prediction using SOPMA for mutacin 1140 leader peptide; h (alpha helix), e (extended strand), c (random coil), t (beta turn). Alpha helical regions are in bold, while random coils are underlined in the leader peptide sequence.

Article Snippet: S. mutans ATCC 55676 , 2264.63 ± 1.

Techniques: Labeling, Sequencing, Produced

Journal: MicrobiologyOpen

Article Title: The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics

doi: 10.1002/mbo3.222

Figure Lengend Snippet: Strains and plasmids used in this study. All mutations were made in the wild-type strain JH1140. All the plasmids came from Escherichia coli DH5 α cells

Article Snippet: S. mutans ATCC 55676 , 2264.63 ± 1.

Techniques: Plasmid Preparation, Cloning

Journal: MicrobiologyOpen

Article Title: The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics

doi: 10.1002/mbo3.222

Figure Lengend Snippet: Identification of structural elements within the mutacin 1140 leader peptide that are important for bioactivity. (A) Covalent structure representation of the mutations made on the leader peptide. Bioactivity for leader peptide mutants were measured as the percent difference in the zone of inhibition between wild-type and the mutant strains. Δ lanA strain was used as a negative control for bioactivity in all experiments. The change in activity was measured for: (B) N-terminal deletions of the leader peptide, (C) mutations in the proposed FNLD-type box, (D) mutation in a new box, For each mutation, the bioactivity has been compared to the activity of wild-type S. mutans JH1140 strain. Statistical method used was Student t -test and the asterisk signifies statistical significance ( P < 0.05).

Article Snippet: S. mutans ATCC 55676 , 2264.63 ± 1.

Techniques: Inhibition, Mutagenesis, Negative Control, Activity Assay

Journal: MicrobiologyOpen

Article Title: The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics

doi: 10.1002/mbo3.222

Figure Lengend Snippet: Cyanylation of free thiols by CDAP. (A) MALDI-TOF MS of peptide from Δ(-40-33) strain (A1) and CDAP-treated peptide (A2); (B) MALDI-TOF MS of peptide from AALF strain (B1) and CDAP-treated peptide (B2); (C) MALDI-TOF MS of peptide from ΔL-20 strain (C1) and CDAP-treated peptide (C2); (D) MALDI-TOF MS of peptide from ΔF-19 (D1) and CDAP-treated peptide (D2); (E) MALDI-TOF MS of peptide from F-19A (E1) and CDAP-treated peptide (E2); (F) MALDI-TOF MS of positive control peptide resact (F1) and CDAP-treated peptide (F2). None of the isolated peptides from S. mutans -mutant strains reacted with CDAP, while the positive control was cyanylated.

Article Snippet: S. mutans ATCC 55676 , 2264.63 ± 1.

Techniques: Positive Control, Isolation, Mutagenesis

Journal: MicrobiologyOpen

Article Title: The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics

doi: 10.1002/mbo3.222

Figure Lengend Snippet: MALDI-MS data for isolated mutacin 1140 products from Streptococcus mutans JH1140

Article Snippet: S. mutans ATCC 55676 , 2264.63 ± 1.

Techniques: Isolation

Journal: bioRxiv

Article Title: Deregulated Myt3 translation predisposes islet β-cells to dysfunction under obesity-induced metabolic stress

doi: 10.1101/2025.05.11.653323

Figure Lengend Snippet: (A) Myt3 exons with detectable expression in adult mouse β cells. Only the first 9 of the 25 exons are shown (not in scale). (B) The presence of uORFs in the 5’end of the two primary Myt3 transcripts. (C) Reporter constructs that are used to test stress-induced translation. Note that RLuc and FLuc transcription are all regulated by a TeoO promoter/enhancer, ensuring a constant ratio of their transcription. Also note that in the T2RM construct, a 12 bp sequence (5’-AGCTTTAATGAA-3’) was inserted to disrupt the overlapping uORF. (D) Reporter assay results with or without ER stress response induced by a three-hour heat shock at 42-43 °C. Presented are the ratios between FLuc/RLuc. Each dot represents an independent experiment, each having 2-3 technical duplicates. P-values are from paired t-tests with two-tailed type two errors.

Article Snippet: The cDNAs of RLuc and FLuc plus polyA signals from a vector from Addgene (#226464) were PCR amplified and cloned into a vector containing a bi-directional TetO enhancer/promoter (Addgene, #96963), producing general vector pYW1134.

Techniques: Expressing, Construct, Sequencing, Reporter Assay, Two Tailed Test

Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Molecular changes in solitary fibrous tumor progression

doi: 10.1007/s00109-019-01815-8

Figure Lengend Snippet: Characterization of the molecular and histopathological features of the index SFT case. a Diagram of the primary and metastatic sites of the index case. b A schematic pre-mRNAs of the fusion variant 2a from the RNA-sequencing experiment. Bottom sequences in black are the reads that map onto the chimeric exon-exon splicing junction. c The fusion variant 2a was confirmed by RT-PCR and Sanger sequencing. d Comparison of CD34, Ki-67, and STAT6 immunohistochemical staining and counterpart H&E staining in the primary and metastatic tissues

Article Snippet: The CD34 antibody (Thermo Fisher Scientific, Inc., MA1-22646, 1:100 dilution) and Ki-67 antibody (Novocastra, Buffalo Grove, IL, USA, NCL-Li-Ki-67-MM1, 1:50 dilution) were used.

Techniques: Variant Assay, RNA Sequencing, Reverse Transcription Polymerase Chain Reaction, Sequencing, Comparison, Immunohistochemical staining, Staining